Investors in Ultragenyx Pharmaceutical Inc. Have Rare Opportunity to Lead Securities Fraud Case

Investors who hold shares in Ultragenyx Pharmaceutical Inc. (Nasdaq: RARE) may have a unique opportunity to take the lead in a securities fraud lawsuit brought by the Schall Law Firm. It is advised that investors who purchased the Company’s securities between August 3, 2023, and December 26, 2025, should contact the law firm before April 6, 2026. The investigation focuses on the alleged violations of the Securities Exchange Act of 1934, specifically §§10(b) and 20(a), as well as Rule 10b-5, enforced by the U.S. Securities and Exchange Commission.

The main issue revolves around Ultragenyx Pharmaceutical Inc.’s misleading statements to the market regarding the efficacy of its drug candidate for patients with Osteogenesis Imperfecta, a genetic disorder characterized by brittle bones. The company provided investors with an overly optimistic outlook on the drug’s effectiveness, which was subsequently contradicted by the results of the Phase III ORBIT study. This study failed to demonstrate a significant reduction in the annual fracture rate, thereby discrediting the company’s earlier claims.

As a result of these discrepancies, investors who bought shares in Ultragenyx based on the false information suffered significant financial losses when the truth was revealed to the public. The Schall Law Firm is prepared to represent shareholders in this class action lawsuit against Ultragenyx Pharmaceutical Inc. for damages incurred due to the alleged securities fraud committed by the company.

It is crucial for affected investors to join the lawsuit to seek recovery for their losses. The Schall Law Firm specializes in securities class action lawsuits and shareholder rights litigation, offering global representation for investors seeking justice in cases of securities fraud. This press release serves as a call to action for investors who have been impacted by Ultragenyx Pharmaceutical Inc.’s misleading statements to come forward and participate in the legal proceedings.

In conclusion, investors who were misled by Ultragenyx Pharmaceutical Inc.’s inaccurate claims about the effectiveness of its drug candidate for Osteogenesis Imperfecta must act swiftly to assert their rights and seek compensation through the ongoing securities fraud lawsuit led by the Schall Law Firm. By coming forward and joining the case, affected shareholders can potentially recover the financial losses they suffered as a result of the company’s alleged misconduct.